KRAS and neoplasm: We additionally found that ALK fusion was more frequent in younger patients, and that patients harboring mutations in KRAS or LBP1B had significantly larger tumor diameters as compared to patients with wild-type KRAS, suggesting that KRAS or LBP1B alterations are associated with LAMPC tumor progression.